Hanmi Pharm wins South Korea approval for Epe auto-injector obesity drug

South Korea's Ministry of Food and Drug Safety has granted marketing authorization for Hanmi Pharmaceutical's Epe auto-injector (efpeglenatide), a GLP-1 therapy for chronic weight management in adults. The drug, approved in five strengths, is positioned to complement diet and exercise.